Placebo Tiragolumab
Sponsors
F. Hoffmann-La Roche AG
Conditions
Hepatocellular Carcinoma (HCC)Non-small cell lung cancer (NSCLC)Small cell lung cancer (SCLC)
Phase 3
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Active, not recruitingCTIS2023-503422-39-00
Start: 2023-10-20Target: 182Updated: 2026-01-07
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
CompletedCTIS2022-502482-17-00
Start: 2020-05-19End: 2025-11-05Target: 192Updated: 2025-08-11
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
CompletedCTIS2022-502988-37-00
Start: 2020-06-19End: 2025-07-31Target: 90Updated: 2025-04-10